Dong et al. (Asian; China) reported a significant association between the TYMS rs3786362 SNP (c.381A>G; synonymous; Glu127Glu) with grade 2–3 HFS in 288 patients with CRC (stages I–IV) treated with capecitabine-based regimens (OR = 0.38; 95% CI = 0.21–0.70; p = 1.89 × 10–3 for AA vs. AG vs. GG) [32]. Here, TYMS is linked to colorectal carcinoma.